Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers

DISEASE CHARACTERISTICS: * Histologically proven primary or metastatic malignant supratentorial anaplastic glioma * Newly diagnosed or recurrent * No diffusely infiltrating or multifocal tumor * No tumor with subependymal spread * Resection of glioma and placement of an intralesional catheter into the surgical cavity required before study * Measurable lesion on enhanced CT scan or MRI * No measurable enhancing lesion greater than 1.0 cm beyond cavity margin * Neoplastic cell reactivity with tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a monoclonal murine antibody PATIENT CHARACTERISTICS: Age: * 3 and over Performance status: * Karnofsky 50-100% Hematopoietic: * Absolute neutrophil count greater than 1,000/mm\^3 * Platelet count greater than 100,000/mm\^3 Hepatic: * Bilirubin less than 1.5 mg/dL * AST less than 1.5 times normal * Alkaline phosphatase less than 1.5 times normal Renal: * Creatinine less than 1.2 mg/dL Other: * Not pregnant * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 6 weeks since prior chemotherapy unless unequivocal evidence of tumor progression Endocrine therapy: * Corticosteroids allowed if at lowest possible dose and dose stable for at least 10 days prior to entry Radiotherapy: * At least 3 months since prior radiotherapy to site of measurable disease unless unequivocal evidence of tumor progression Surgery: * See Disease Characteristics